


PTO 892 DEAFCE 1994		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		SERIAL NUMBER 09/460,216		Art Unit 1648		Attachment to Paper Number 10	
NOTICE OF REFERENCES CITED									
				APPLICANTS : Allaway, G., <i>et al.</i>					
U.S. PATENT DOCUMENTS									
*		DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE		
FOREIGN PATENT DOCUMENTS									
*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	PERTINENT DRW SPEC	
*		OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
		Howard, O.M.Z., <i>et al.</i> , 1998, "Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function", J. Leuk. Biol.64:6-13.							
*		Berger, E. A., <i>et al.</i> , 1999, "Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease", Annu. Rev. Immunol. 17:657-700.							
		Proudfoot, A. E. I., <i>et al.</i> , 1999, "Chemokine receptors: future therapeutic targets for HIV?", Biochem. Pharmacol. 57:451-463.							
		Proudfoot, A. E. I., <i>et al.</i> , 2000, "The strategy of blocking the chemokine system to combat disease", Immunol. Rev. 177:246-256.							
		Öberg, B. and L. Vrang, 1990, "Screening for new agents", Eur. J. Clin. Microbiol. Infect. Dis. 9(7):466-471.							
		Yarchoan, R. and S. Broder, 1992, "Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development", J. Enzyme Inhibit. 6:99-111.							
		Flexner, C. and C. Hendrix, 1997, "Pharmacology of antiretroviral agents", in <i>AIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition</i> , De Vita, V., <i>et al.</i> , eds., Lippincott-Raven Publishers, pp. 479-493.							

EXAMINER  Jeffrey S. Parkin, Ph.D.	DATE 09/26/01	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a).) PAGE 1 OF 1
---	----------------------	---